| Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript |
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Nichol Ochsner - Vice President Neil McFarlane - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Josh Schafer - Chief Commercial Officer Adrian Quartel - Chief Medical Officer Conference Call Participants Sumant Kulkarni - Canaccord Jason Butler - Citizens Eddie Hickman - Guggenheim Lachlan Hanbury - Brown with William Blair Operator Good afternoon and thank you for joining Zevra's First Quarter 2025 Financial Results and Corporate Update Conference Call. Today's call is being recorded, and will be available via the Investor Relations section of the company's website later today. |
seekingalpha.com |
2025-05-14 02:45:32 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates |
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.40 per share a year ago. |
zacks.com |
2025-05-13 22:20:34 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call |
Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025 Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025 |
globenewswire.com |
2025-05-06 11:30:00 |
Czytaj oryginał (ang.) |
| Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism |
CELEBRATION, Fla., April 17, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announces the publication of “Mechanistic insights into arimoclomol mediated effects on lysosomal function in Niemann-pick type C disease” in Molecular Genetics and Metabolism. |
globenewswire.com |
2025-04-17 11:30:00 |
Czytaj oryginał (ang.) |
| Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million |
CELEBRATION, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $150 million. |
globenewswire.com |
2025-04-07 11:30:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics Files Preliminary Proxy |
Confirms Receipt of Two Director Nominees from Daniel J. Mangless Stockholders Are Not Required to Take Action at This Time CELEBRATION, Fla. |
globenewswire.com |
2025-03-31 20:12:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript |
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Nichol Ochsner - VP, IR and Corporate Communications Neil McFarlane - President and CEO LaDuane Clifton - CFO Joshua Schafer - Chief Commercial Officer and EVP, Business Development Adrian Quartel - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Jason Butler - Citizens JMP Sumant Kulkarni - Canaccord Oren Livnat - H.C. Wainwright Samantha Corwin - William Blair Eddie Hickman - Guggenheim Securities Operator Good afternoon, and thank you for joining Zevra's Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call. |
seekingalpha.com |
2025-03-11 22:16:34 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates |
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.40 per share a year ago. |
zacks.com |
2025-03-11 21:15:22 |
Czytaj oryginał (ang.) |
| Zevra Reports Full Year 2024 and Fourth Quarter Financial Results |
FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host conference call and webcast today, Mar. 11, 2025, at 4:30 p.m. ET CELEBRATION, Fla. |
globenewswire.com |
2025-03-11 18:05:00 |
Czytaj oryginał (ang.) |
| Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C |
New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C |
globenewswire.com |
2025-02-28 09:30:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million |
CELEBRATION, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $150 million upon the closing of the transaction, which is expected to take place within 30 to 45 days, subject to customary closing conditions. |
globenewswire.com |
2025-02-27 09:30:00 |
Czytaj oryginał (ang.) |
| Zevra to Report 2024 Fourth Quarter and Full Year Financial Results |
Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ET Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ET |
globenewswire.com |
2025-02-26 11:46:00 |
Czytaj oryginał (ang.) |
| Zevra to Participate at Upcoming Investor Conferences |
CELEBRATION, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will participate at the following March events: |
globenewswire.com |
2025-02-24 18:02:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ |
Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21 st Annual WORLDSymposium |
globenewswire.com |
2025-01-30 09:30:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics to Participate at Upcoming Investor Conferences |
CELEBRATION, Fla., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that members of Zevra's executive leadership team will participate in the following February events. |
globenewswire.com |
2025-01-29 18:05:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 |
CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) (“NBI”) as part of the annual reconstitution of the 2024 Nasdaq indexes. Zevra's inclusion in the NBI will be effective after the U.S. market opens on Monday, December 23, 2024. |
globenewswire.com |
2024-12-17 09:30:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics Announces Organizational Changes |
CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced organizational changes designed to accelerate its transformation into a leading rare disease therapeutics company. |
globenewswire.com |
2024-12-06 19:00:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics to Participate at Upcoming Investor Conferences |
CELEBRATION, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in the following December investor events. |
globenewswire.com |
2024-11-26 09:30:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C |
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra's specialty pharmacy for dispense |
globenewswire.com |
2024-11-21 18:51:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript |
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Nichol Ochsner - VP, IR & Corporate Communications Neil McFarlane - President & CEO LaDuane Clifton - CFO Joshua Schafer - Chief Commercial Officer & EVP, Business Development Conference Call Participants Jason Butler - JMP Securities Louise Chen - Cantor Fitzgerald Samantha Corwin - William Blair Eddie Hickman - Guggenheim Securities Sumant Kulkarni - Canaccord Genuity Oren Livnat - H.C. Wainwright Operator Good afternoon, and thank you for joining Zevra Therapeutics Third Quarter Financial Results and Corporate Update Conference Call. |
seekingalpha.com |
2024-11-13 09:12:12 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates |
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.40 per share a year ago. |
zacks.com |
2024-11-12 21:06:30 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting |
Data show that the NPCCSS swallow score reflects the patient's level of dysfunction Study indicates that a change in score reflects actual improvement or worsening in a patient's swallowing function CELEBRATION, Fla., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Elizabeth Berry-Kravis, M.D. |
globenewswire.com |
2024-11-11 18:36:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 |
CELEBRATION, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference Virtual on Wednesday, Nov. 13, 2024, at 4 p.m. ET. Additionally, management will be available for one-on-one meetings with registered attendees. |
globenewswire.com |
2024-11-06 09:30:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 |
CELEBRATION, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced it will report third quarter financial results and provide a corporate update on Tuesday, Nov. 12, 2024. |
globenewswire.com |
2024-10-31 09:30:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline |
Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-29 13:06:11 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC |
CELEBRATION, Fla., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in a Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC on Thursday, October 17, 2024 at 2 p.m. ET. |
globenewswire.com |
2024-10-10 11:30:00 |
Czytaj oryginał (ang.) |
| Zevra Stock Surges Close to 70% in 3 Months: Here's Why |
The FDA approval for ZVRA's Miplyffa (arimoclomol) capsules in September for treating Niemann-Pick disease type C drives the stock. |
zacks.com |
2024-10-04 16:00:24 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last? |
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-09-25 11:26:11 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 |
KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study CELEBRATION, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a commercial-stage rare disease therapeutics company, today announced that Rene Braeckman, Ph.D. |
globenewswire.com |
2024-09-24 11:30:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C |
MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease |
globenewswire.com |
2024-09-20 16:08:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium |
New clinical efficacy and safety data for arimoclomol as a possible treatment for Niemann-Pick disease type C, including from long-term and real-world settings, demonstrate clinically meaningful reduction in disease progression |
globenewswire.com |
2024-09-06 12:30:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics to Participate at Upcoming Investor Conferences |
CELEBRATION, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will present at upcoming investor conferences during the month of September 2024. Additionally, management will be available for one-on-one meetings with registered attendees at each conference. |
globenewswire.com |
2024-08-29 11:30:00 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript |
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Nicole Oschner - Vice President of Investor Relations and Corporate Communications Neil McFarlane - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Josh Schafer - Chief Commercial Officer and Executive Vice President of Business Development Conference Call Participants Louise Chen - Cantor Fitzgerald Tim Lugo - William Blair Oren Livnat - H.C. Wainwright Operator Hello, and thank you for joining the Zevra Therapeutics Q2 2024 Financial Results and Corporate Highlights Call. |
seekingalpha.com |
2024-08-14 01:45:26 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates |
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.15 per share a year ago. |
zacks.com |
2024-08-13 22:30:31 |
Czytaj oryginał (ang.) |
| Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock |
CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (“Zevra”), today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at an offering price of $6.50 per share, for total gross proceeds of approximately $60.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Zevra. All of the common stock is being offered by Zevra. The offering is expected to close on August 12, 2024, subject to customary closing conditions. In addition, Zevra has granted the underwriters a 30-day option to purchase up to an additional 1,384,615 shares of its common stock at the public offering price, less underwriting discounts and commissions. |
globenewswire.com |
2024-08-09 04:00:00 |
Czytaj oryginał (ang.) |